New combo therapy aims to stop rare HER2-positive salivary gland cancer in its tracks

NCT ID NCT04620187

Recruiting now Disease control Sponsor: Dana-Farber Cancer Institute Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding the targeted drug T-DM1 to standard chemoradiation can prevent HER2-positive salivary gland cancer from returning after surgery. About 37 adults with advanced but removable tumors will receive the drug alongside standard care. Researchers will track cancer recurrence over two years and monitor side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

salivary gland cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HER2 GENE MUTATION SALIVARY GLAND CANCER

Contacts and locations

Locations

Brigham and Women's Hospital
RECRUITING

Boston, Massachusetts, 02115, United States
Dana Farber Cancer Institute
RECRUITING

Boston, Massachusetts, 02115, United States
David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center
RECRUITING

New York, New York, 10021, United States
Memorial Sloan Kettering Basking Ridge
RECRUITING

Basking Ridge, New Jersey, 07920, United States
Memorial Sloan Kettering Bergen
RECRUITING

Montvale, New Jersey, 07645, United States
Memorial Sloan Kettering Cancer Center
RECRUITING

New York, New York, 10065, United States
Memorial Sloan Kettering Commack
RECRUITING

Commack, New York, 11725, United States
Memorial Sloan Kettering Monmouth
RECRUITING

Middletown, New Jersey, 07748, United States
Memorial Sloan Kettering Nassau
RECRUITING

Uniondale, New York, 11553, United States
Memorial Sloan Kettering Westchester
RECRUITING

Harrison, New York, 10604, United States
University of Chicago
RECRUITING

Chicago, Illinois, 60637, United States
University of Washington Medical Center
RECRUITING

Seattle, Washington, 98195, United States
Winship Cancer Institute, Emory University
RECRUITING

Atlanta, Georgia, 30322, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.